FCRL5 and AL amyloidosis: This is despite the fact that they represent a potential biomarker of clinical response for rituximab in rheumatoid arthritis (31) and the observation that FCRL5 gene expression is strongly upregulated on the bone marrow plasma cells of multiple myeloma and Burkitt Lymphoma (20).